A Structural Comparison of Oral SARS-CoV-2 Drug Candidate Ibuzatrelvir Complexed with the Main Protease (M<sup>pro</sup>) of SARS-CoV-2 and MERS-CoV-Reference-Cited by-同舟云学术

A Structural Comparison of Oral SARS-CoV-2 Drug Candidate Ibuzatrelvir Complexed with the Main Protease (M^pro) of SARS-CoV-2 and MERS-CoV

Published:2024-07-30 Issue:8 Volume:4 Page:3217-3227
ISSN:2691-3704
Container-title:JACS Au
language:en
Short-container-title:JACS Au

Author:

Chen Pu¹²,Van Oers Tayla J.³^ORCID,Arutyunova Elena¹²^ORCID,Fischer Conrad³^ORCID,Wang Chaoxiang³,Lamer Tess³^ORCID,van Belkum Marco J.³^ORCID,Young Howard S.¹^ORCID,Vederas John C.³^ORCID,Lemieux M. Joanne¹²^ORCID

Affiliation:

1. Department of Biochemistry, University of Alberta, Edmonton, Alberta T6G 2H7, Canada

2. Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta T6G 2E1, Canada

3. Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada

Funder

Canadian Institutes of Health Research

Canada Foundation for Innovation

National Institute of General Medical Sciences

Ministry of Technology and Innovation, Alberta

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/jacsau.4c00508

Reference41 articles.

1. An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19

2. Remdesivir for the Treatment of Covid-19 — Final Report

3. Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir

4. Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys

5. Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study